RESUMEN
Abstract Background Secukinumab has shown high efficacy in randomized controlled trials in both ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Here, we investigated its real-life effectiveness and tolerability in a cohort of AS and PsA patients. Methods We retrospectively analyzed medical records of outpatients with AS or PsA treated with secukinumab between December 2017 and December 2019. ASDAS-CRP and DAS28-CRP scores were used to measure axial and peripheral disease activity in AS and PsA, respectively. Data were collected at baseline and after 8, 24, and 52 weeks of treatment. Results Eighty-five adult patients with active disease (29 with AS and 56 with PsA; 23 males and 62 females) were treated. Overall, mean disease duration was 6.7 years and biologic-naïve patients were 85%. Significant reductions in ASDAS-CRP and DAS28-CRP were observed at all time-points. Body weight (in AS) and disease activity status at baseline (particularly in PsA) significantly affected disease activity changes. ASDAS-defined inactive disease and DAS28-defined remission were achieved in comparable proportions between AS and PsA patients, at both 24 weeks (45% and 46%) and 52 weeks (65.5% and 68%, respectively); male sex was found an independent predictor of positive response (OR 5.16, P = 0.027). After 52 weeks, achievement of at least low disease activity and drug retention were observed in 75% of patients. Secukinumab was well-tolerated and only mild injection-site reactions were recorded in 4 patients. Conclusion In a real-world setting, secukinumab confirmed great effectiveness and safety in both AS and PsA patients. The influence of gender on treatment response deserves further attention.
RESUMEN
Objective To investigate the values of ASAS-endorsed disease activity score (ASDAS) and routine assessment of patient index data 3 (RAPID3) in assessing disease activity of patients with ankylosing spondylitis (AS) in China. Methods Questionnaires were used to obtain the general information and disease activity of 82 AS patients; and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were measured in the venous blood samples. Correlation analysis and kappa consistency test were used to compare the value of traditional measures for assessing disease activity of AS including Bath ankylosing spondylitis disease activity index (BASDAI) with the new measures including ASDAS and RAPID3. Results ASDAS-CRP and RAPID3 had a good consistency in assessing AS activity (kappa value: 0.788), but both of them had poor consistency with BASDAI (kappa values: 0.342, 0.367). BASDAI, ASDAS and RAPID3 were well correlated with doctor global assessment (DOCGL) and patient global assessment (PATGL), and ASDAS and RAPID3 had stronger correlation with DOCGL and PATGL than BASDAI did (the r values of ASDAS-CRP, ASDAS-ESR, RAPID3, and BASDAI with DOCGL were 0.684, 0.720, 0.642 and 0.576; and those with PATGL were 0.822, 0.816, 0.851 and 0.725, respectively). Conclusion ASDAS is superior to BASDAI in assessing the disease activity of AS, making it a new promising index for evaluating disease activity and worth promoting. RAPID3 is convenient, simple, and independent to laboratory findings, and it has a good reliability and validity in evaluating disease activity of AS.